Assembly Biosciences (NASDAQ: ASMB) is a clinical-stage biotechnology company committed to bringing finite and curative therapies to the 270 million people living with hepatitis B virus (HBV) worldwide. A pioneer in the development of a new class of potent, oral core inhibitor drug candidates, Assembly Bio’s approach aims to break the complex viral replication cycle of HBV to free patients from a lifetime of therapy. Assembly Bio’s strategy toward cure includes a leading portfolio of more potent, next-generation core inhibitors, proof-of-concept combination studies and a research program focused on the discovery of novel HBV targets. 

Biotechnology

Assembly Biosciences

Jason Okazaki

Anuj Gaggar

Zhixin Z.

Suzette DeVito

Qi Huang

John O. Gunderson

Grace Wang

Gayan Bogollaga

Nicole S. White

William Delaney

Jennifer Troia

The Clinical and Regulatory Operations team at Assembly Biosciences is responsible for overseeing the clinical trials and ensuring regulatory compliance to advance the development of innovative HBV therapies. This includes planning and executing clinical studies, managing trial sites, ensuring data integrity, and liaising with regulatory authorities to secure approvals for next-generation core inhibitors and combination therapies.

Clinical and Regulatory Operations

Directors and Senior Directors Team

Scientific Team

Leadership Team

Clinical and Regulatory Operations

About

Team members

Other teams at Assembly Biosciences

Directors and Senior Directors Team

Scientific Team

Leadership Team